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Introduction
Left ventricular (LV) geometric remodeling, like con-
centric ventricular hypertrophy, has been shown to be
associated with elevated cardiovascular morbidity and
mortality1–5. Hypertension as a primary cause of LV
remodeling, together with other metabolic abnormal-
ities6,7, characterizes cardiac structural and functional
abnormalities. Both experimental and clinical data
have already demonstrated the association between
phenotypic ventricular remodeling with aging and
serologic evidence of myocardial fibrosis linking to
ventricular stiffness8, diastolic dysfunction9 and, even-
tually, heart failure development10–12. LV remodeling,
a marker of cardiac target organ damage, may thus
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SUMMARY
Background: Left ventricular (LV) remodeling has been shown to impart prognostic significance in previous studies.
However, the underlying exact mechanisms involved and interactions between LV geometry alterations and
age with other clinical and biochemical variables in general population have not been well established.
Methods: A total of 406 consecutive subjects were enrolled in a health evaluation center-based population
study (mean age, 51.5 ± 10.9 years; 42% women). Data including baseline characteristics, echocardiography,
biochemistry and biomarkers were all collected and evaluated. Univariate and multivariate regression analysis
was performed to test the relationship between relative wall thickness (RWT) and other variables. We also
divided the subjects into older and younger groups, compared RWT between the two groups, and analyzed the
distribution of LV geometry in these groups.
Results: The prevalence of diabetes and hypertension in our study population was relatively small (11.6% and
16.5%, respectively). The most common type of LV geometry in our study was normal (67.5%) and concentric
remodeling (30.3%) compared with a relatively small proportion of concentric LV hypertrophy (1.5%) and eccentric
hypertrophy (< 1%). Of all 406 subjects evaluated, age, uric acid, height, systolic blood pressure and serum
insulin level were all independent factors associated with RWT in a multivariate regression model.
Conclusion: In our study, we revealed that aging, together with baseline blood pressure and serum biochemistries,
were associated with LV geometric alterations. These data suggest that the LV remodeling process actually
involves dynamic and complex interactions with multiple metabolic factors in an unselected general population
in Taiwan. [International Journal of Gerontology 2009; 3(1): 66–74]
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serve as an easy and clinically feasible surrogate for
cardiac functional abnormality in daily practice.
LV geometry can actually be categorized according
to relative wall thickness (RWT) and LV mass index13,14,
including normal geometry, concentric remodeling
(increased RWT but normal LV mass), concentric hyper-
trophy (increased RWT and LV mass) and eccentric
hypertrophy (normal RWT but increased LV mass).
Concentric remodeling, as a trivial form of remodeling,
may occur before hypertrophy. Although it has been
shown that concentric remodeling may be related to
various cardiovascular risk factors and comorbidities
so far, a debate remains regarding the minor pheno-
type of concentric remodeling and cardiovascular
prognosis3–5,15. Furthermore, the association or rela-
tionship between LV concentric geometry and other
parameters including age, clinical variables and bio-
chemistries in an Asian population has not been well
established. Thus, we sought to investigate the deter-
minants and the association between these LV geomet-
ric alterations and clinical or metabolic factors from
biochemical assays in a general population.
Materials and Methods
Study setting and subject enrollment
The design of this study was approved by the local
ethics committee in accordance with the Declaration
of Helsinki. We consecutively enrolled participants from
the health evaluation center of Mackay Memorial
Hospital, a medical center in Taipei, Taiwan, during the
period from January 2003 to December 2006. A thorough
review of medical history, physical examination, 12-lead
electrocardiogram and chest X-ray were all performed.
All baseline characteristics including age, height, weight,
body mass index and routine laboratory data regarding
routine biochemistries (including liver, renal profiles),
complete blood cell counts and biomarkers were taken.
Cuff blood pressures at rest were taken by medical
staff blinded to the other test results. Patients with
decompensated heart failure, poorly controlled diabetes
(hemoglobin A1c [HbA1c], > 9.0%) or renal insufficiency
(creatinine, > 2.5 mg/dL) were excluded in our study.
Patients with diabetes had a fasting glucose level
> 126 mg/dL and were currently using diabetes med-
ication or had a positive medical history. Hypertension
was defined in patients with a systolic blood pressure
>140mmHg, with a diastolic blood pressure >90mmHg,
currently using antihypertensive medication, or with 
a positive medical history.
Echocardiography, LV geometry and LV mass
quantification
Transthoracic echocardiography was performed by 
a single experienced technician blinded to other study
results using a Hewlett-Packard instrument (Sonos 5500,
Philips, The Netherlands) equipped with a 2.5 MHz
transducer. Wall thickness and dimensions of the LV
were collected. RWT was calculated as the ratio of two
times the end-diastolic LV posterior wall thickness
(LVPWd) to end-diastolic LV internal diameter (LVIDd)
measured by the M-mode from parasternal long-axis
view. LV ejection fraction was calculated by the modi-
fied Teichholz method16. LV mass (g) was determined
from the M-mode measurement using the formula
according to American Society of Echocardiography14.
LV mass index (g/m2) was defined as the ratio of LV mass
to body surface area. All echocardiographic measures
represented the average of consecutive three heart
cycles. LV concentric geometry was defined as those
with RWT > 0.42. LV mass index > 95 g in women and
> 115 g in men were further defined as LV hypertrophy
as in previous studies2. Patients with at least a moderate
degree of valvular heart disease, pulmonary hyperten-
sion (systolic pulmonary arterial pressure, > 50 mmHg),
previous cardiac surgery, existence of congenital heart
disease or LV ventricular ejection fraction < 50% were
excluded in this study.
Biochemistry and biomarkers
Fasting plasma glucose and other laboratory data includ-
ing lipid and renal profiles were obtained by a Hitachi
7170 automatic analyzer (Hitachi Corp. Hitachinaka,
Ibaraki, Japan), and immunoreactive insulin was mea-
sured by radioimmunoassay (PerkinElmer Automatic
Gamma Counter 1470; PerkinElmer, Waltham, MA, USA).
HbA1c level was assessed by high-performance liquid
chromatography (Bio-Rad Variant II; Bio-Rad Labora-
tories, Hercules, CA, USA). Insulin resistance was calcu-
lated using the homeostasis model assessment−insulin
resistance (HOMA-IR) method: HOMA-IR = fasting glu-
cose (mmol/L) × fasting insulin (μU/mL)/22.5. Complete
blood counts were assessed by Coulter Gen-S (Beckman
Coulter, Miami, FL, USA). Biomarkers including high-
sensitivity C-reactive protein (hs-CRP; Immulite assay;
Siemens Healthcare Diagnostics GmbH, Eschborn,
Germany) and pro-B-type natriuretic peptide (pro-BNP)
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level by electrochemiluminescence immunoassay (Roche
E170; Roche Diagnostics GmbH, Mannheim, Germany)
were collected.
Statistics
Continuous data were presented as mean ± standard
deviation and were compared with an unpaired t test
or Mann-Whitney U test as appropriate. Categorical or
proportional incidence data were expressed as ratios
and compared by the Chi-squared or Fisher’s exact test.
Backward stepwise multivariate regression analysis was
used to select the most powerful models for the inde-
pendent variables associated with RWT in our study.
Significance and relationships associated with RWT were
chosen by univariate regression. A p value < 0.1 was
used for the multivariate model. Potential colinearity of
different variables entered into the multivariate model
was tested by variance inflation factor (VIF) to ensure
that these variables were not entered simultaneously.
All VIFs < 5 were assumed to be efficient in the selection
of such variables without significant colinearity. The
data were analyzed with the software package STATA
8.0 (StataCorp, College Station, TX, USA).
RWT and other variables were compared in different
age groups (≥ 60 and < 60 years). Parameters were also
compared between the groups with concentric geometry
or without concentric geometry in the two age groups.
The p value was set for a two-tailed probability, and a
p value < 0.05 was considered statistically significant.
Results
Baseline characteristics
A total of 942 subjects were initially screened and
reviewed, and finally 406 (mean age, 51.5 ± 10.9 years;
42% women) participants were enrolled in our study
after exclusion for inadequate criteria or missing data.
The baseline demographic data and echocardiographic
variables are displayed in Tables 1 and 2, respectively.
There were a total of 274 patients (67.5%) with normal
LV geometry, 123 (30.3%) had concentric remodeling
pattern, six (1.5%) had concentric hypertrophy and
three (< 1%) had eccentric hypertrophy according to
our study definition. The final population of the pres-
ent study consisted of 47 cases (11.6%) of diabetes and
67 cases (16.5%) of hypertension with 15 participants
(3.7%) on regular medication for hyperlipidemia (either
fibric acid or statin therapy), 66 participants (16.3%) on
anti-hypertension therapy and 24 participants (5.9%)
on hypoglycemic agents.
The whole study population was divided into two
groups, including the older group (n = 76) and the
younger group (n = 330). Baseline characteristics, labo-
ratory tests, including biochemistries, biomarkers and
complete blood counts, and echocardiographic find-
ings were compared (Tables 1 and 2). The average age
of the older and younger groups was 67.8 ± 6.3 years
and 47.6 ± 7.8 years, respectively (p < 0.01). Compared
with the younger group, the older group had shorter
height, greater waist and higher systolic blood pressure
(p < 0.05). The mean systolic blood pressures of the
older and younger group were 130.4 ± 18.5 mmHg and
118.0 ± 15 mmHg, respectively (p < 0.001). A borderline
higher uric acid level was observed in the older group
when compared with the younger one (p = 0.05). More-
over, higher blood urea nitrogen, glucose, HbA1c, 
hs-CRP and pro-BNP, and lower serum hemoglobin,
platelet counts and albumin level were all found in
the older group (p < 0.05).
Echocardiography and LV geometry
Table 2 shows that LV wall thickness were thicker in
the older when compared with the younger group,
including end-diastolic interventricular septum (11.3 ±
1.8 mm vs. 10.2 ± 1.7 mm; p < 0.001) and end-diastolic
posterior wall (11±1.3mm vs. 10.1±1.4mm; p<0.001).
There was a trend toward higher ascending aortic
diameter in the younger group that did not reach sta-
tistical significance (p = 0.13), while the aortic root
diameter seemed to be larger in the younger group
(p = 0.04). There was no significant difference in left
atrial diameter between these two groups assessed by
the traditional M-mode method (p = 0.18). The global
ventricular ejection fraction was within normal limits
(66.4% ± 5.9%), suggesting a fair cardiac performance in
our population. In the older group, the LV mass (183.4±
41.1 g vs. 156.7 ± 38.7 g; p < 0.001) and LV mass index
(72.5 ± 17.2 g/m2 vs. 58.1 ± 13.7 g/m2; p < 0.001) were
significantly larger, and that RWT was also larger in the
older than the younger group (42.7% ± 6.6% vs. 39.3% ±
6.7%; p < 0.001). The proportion of normal geometry,
concentric remodeling, concentric hypertrophy and
eccentric hypertrophy was 51.3%, 38.2%, 6.6% and 4.0%,
respectively, in the older group, and 71.2%, 28.5%,
0.3% and 0%, respectively, in the younger group.
We also tested the independence of RWT and age
by 2 × 2 categories using the Chi-squared test with a
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partition value of 0.42 and age of 60 years. This compar-
ison showed that the distribution in the two categories
was not randomly aligned but was really arranged in a
different distribution (χ2 = 7.25; p = 0.0071).
Independent factors and associated determinants
of LV geometric alterations
Univariate regression model revealed that increasing
age, lower body height, higher body weight, larger
waist circumference, higher systolic blood pressure,
higher biochemistry levels including serum blood urea
nitrogen, creatinine, HbA1c, uric acid, insulin, homocys-
teine were all significantly associated with higher RWT
(p < 0.10).
These parameters were then enrolled into stepwise
multivariate regression model and only increasing age,
higher uric acid, lower body height, higher systolic blood
pressure, higher insulin and a trend toward higher
creatinine level remained as significant independent
variables associated with higher RWT (Table 3). All vari-
ables had a VIF of < 5, which safely precluded the pos-
sibility of potential colinearity. The linear regression,
presented as a scatter plot between RWT and age, is
shown in Figure 1.
The associations between RWT and age relating to
other metabolic factors are displayed in Figure 2 by a
bar plot showing quartiles of each variable, which helps
illustrate the complex interaction of aging and other
variable factors on the degree of LV geometric alter-
ations. Similar to our other observations, increasing
age and higher serum metabolic factors were associated
with higher RWT, with a trend toward higher RWT with
increasing age and decreased renal function defined
by serum creatinine level.
Table 1. Baseline characteristics and biochemistries in different age groups*
Age ≥ 60 (n = 76) Age < 60 (n = 330) p
Male/female ratio 1.17:1 1.43:1 –
Age (yr) 67.8 ± 6.3 47.6 ± 7.8 < 0.001
Height (cm) 159.4 ± 8.5 164.1 ± 8.3 < 0.001
Weight (kg) 63.4 ± 10.3 65.7 ± 12 0.077
Body mass index (kg/m2) 24.9 ± 3.6 24.3 ± 3.6 0.2
Buttock (cm) 92.9 ± 6.5 93.5 ± 7.1 0.53
Waist (cm) 84.8 ± 9.7 81.9 ± 10.2 0.027
SBP (mmHg) 130.4 ± 18.5 118.0 ± 15 < 0.001
DBP (mmHg) 74.2 ± 8.2 73.9 ± 9.6 0.93
Heart rate (/min) 72.9 ± 10 73.8 ± 10.7 0.52
Hemoglobin (g/dL) 13.7 ± 1.3 14.5 ± 1.5 < 0.001
Platelets (× 103/μL) 247.4 ± 62.5 267.4 ± 54.7 0.011
Albumin (g/dL) 4.3 ± 0.3 4.4 ± 0.2 < 0.001
Alk-P (IU/L) 75.0 ± 23.4 68.1 ± 17.7 0.015
sGPT (IU/L) 26.4 ± 15.1 32.4 ± 27.8 0.012
BUN (mg/dL) 13.1 ± 3.98 11.4 ± 3.3 0.001
Glucose AC (mg/dL) 106.7 ± 28.6 98.5 ± 20.9 0.016
Glucose PC (mg/dL) 141.3 ± 60 111.4 ± 39.9 < 0.001
Hemoglobin A1c (%) 5.8 ± 0.9 5.5 ± 0.8 0.0077
Uric acid (mg/dL) 6.2 ± 1.4 5.9 ± 1.3 0.05
hs-CRP 0.29 ± 0.5 0.19 ± 0.4 0.003
Pro-BNP (pg/mL) 84.9 ± 115.1 32.3 ± 91.3 < 0.001
Smoking 13 (17.1) 77 (23.3) 0.18
Anti-lipid agents 29 (38.2) 96 (29.1) 0.17
Medication for hypertension 29 (38.2) 37 (11.2) < 0.001
Medication for diabetes 10 (13.2) 14 (4.2) 0.004
*Data are presented as mean ± standard deviation or n (%). SBP = systolic blood pressure; DBP = diastolic blood pressure; Alk-P = alkaline
phosphatase; sGPT = serum glutamate pyruvate transaminase; BUN = blood urea nitrogen; AC = ante cibum; PC = post cibum; hs-CRP = high-
sensitivity C-reactive protein; pro-BNP = pro-B-type natriuretic peptide.
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Discussion
Our current data support that even in a population
with a low prevalence of diabetes, hypertension and
relatively preserved global ventricular systolic func-
tion, a relationship between LV structural alterations
and increasing age, systolic blood pressure or other
metabolic abnormalities remained in a Taiwanese
population.
With increased age, systolic blood pressure tends to
elevate in conjunction with the progressive widening of
pulse pressure and vascular stiffness, leading to higher
incidence of cardiovascular diseases and stroke8,17,18.
While the vascular stiffness increases, the myocardium
Table 3. Multivariable regression analysis of independent clinical and other metabolic factors associated with relative wall
thickness
Variables β SE p 95% confidence interval VIF
Age (/10 yr) 0.82715 0.33711 0.015 (0.1643904, 1.489912) 1.77
Uric acid (mg/dL) 0.92307 0.28514 0.001 (0.3624922, 1.483654) 1.7
Body height (cm) −0.1987 0.0471 < 0.001 (−0.2913333, −0.1061324) 1.5
SBP (/10 mmHg) 0.47389 0.20746 0.023 (0.0660301, 0.8817431) 1.44
Insulin (mU/mL) 0.19103 0.08144 0.019 (0.0309182, 0.3511515) 1.23
Creatinine (mg/dL) 3.96155 2.15934 0.067 (−0.2836751, 8.206782) 1.09
SE = standard error; VIF = variance inflation factor; SBP = systolic blood pressure.
Table 2. Echocardiographic data and distribution of left ventricular (LV) geometry in different age groups*
Age ≥ 60 (n = 76) Age < 60 (n = 330) p
Ascending aortic diameter (mm) 32.6 ± 4.1 31.8 ± 4.0 0.13
Aortic root diameter (mm) 19.8 ± 2.4 20.4 ± 2.3 0.04
Left atrial diameter (mm) 34.5 ± 5.5 32.6 ± 12.1 0.18
EF slope† (mm/s) 68.6 ± 25.5 88.2 ± 26.8 < 0.001
IVSd (mm) 11.3 ± 1.8 10.2 ± 1.7 < 0.001
LVPWd (mm) 11 ± 1.3 10.1 ± 1.4 < 0.001
LVIDd (mm) 47.2 ± 4 46.5 ± 4 0.22
LVIDs (mm) 30.2 ± 3.3 29.4 ± 3.4 0.11
LVEDV (mL) 104 ± 20.6 101.1 ± 20.5 0.3
LVESV (mL) 35.8 ± 9.5 33.9 ± 9.6 0.14
LVEF (%) 65.8 ± 5.7 66.5 ± 5.9 0.42
LV mass (g) 183.4 ± 41.1 156.7 ± 38.7 < 0.001
LV mass index (g/m2) 72.5 ± 17.2 58.1 ± 13.7 < 0.001
RWT (%) 42.7 ± 6.6 39.3 ± 6.7 < 0.001
LV hypertrophy (%) 10.5 0.3 < 0.01
RWT > 0.42 (%) 44.7 28.8 < 0.01
LV geometric patterns < 0.05
Normal geometry 39 (51.3) 235 (71.2) –
Concentric remodeling 29 (38.2) 94 (28.5) –
Concentric hypertrophy 5 (6.6) 1 (0.3) –
Eccentric hypertrophy 3 (4.0) 0 (0.0) –
*Data are presented as mean ± standard deviation or n (%); †mitral valve early diastolic closing velocity by M-mode echocardiography. IVSd =
end-diastolic interventricular septum; LVPWd = end-diastolic LV posterior wall; LVIDd = end-diastolic LV internal dimension; LVIDs = end-systolic LV
internal dimension; LVEDV = LV end-diastolic volume; LVESV = LV end-systolic volume; LVEF = LV ejection fraction; RWT = relative wall thickness.
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is implicated by diastolic dysfunction and structural
remodeling with aging8,19–21. de Simone et al.9 reported
the association between LV concentric geometric changes
and impaired relaxation in patients with hypertension.
Other comorbidities such as diabetes6,22 or renal dys-
function7 further accelerate ventricular structural and
geometric changes. The alterations of ventricular geom-
etry actually include concentric remodeling, concentric
hypertrophy and eccentric hypertrophy. The importance
of significant LV remodeling like ventricular hypertrophy
in predicting cardiovascular risk is well established1,2,4,
but the data is inconsistent in the minor form of con-
centric remodeling3–5,15. Clinical factors including race,
gender, body size and age have been reported to relate
to LV hypertrophy23–25. In addition, the relationship of
LV concentric remodeling rather than hypertrophy with
several components of insulin resistance syndrome was
also found in elderly men26. In the present study, we did
observe that after multivariate adjustment, age, systolic
blood pressure and serum insulin level were highly
associated with the LV geometric alterations in terms
of concentric remodeling. A mild relationship between
renal function in terms of serum creatinine level and
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Figure 1. Scatter plot and linear regression between relative
wall thickness (RWT) and age. With aging, the RWT tends to
increase in a linear fashion.
Figure 2. Relationship between relative wall thickness (RWT) and age and other variables. Numbers 1–4 in the scales of age
and other variables represent four quartiles of each variable. Higher systolic blood pressure (upper left panel), higher serum
insulin level (upper right panel) and higher uric acid level seemed to be associated with aging, as well as higher RWT.
Although there is a trend indicating poorer renal function relating to higher RWT and aging, this finding is statistically 
non-significant. Cre = creatinine; SBP = systolic blood pressure.
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RWT, although insignificant after multivariate adjust-
ment, was observed in the current data. One possible
reason could be the relatively preserved renal function
(creatinine range, 0.5–1.3 mg/dL) in our study popula-
tion that made this impact trivial or this clinical effect
less obvious. Biomarkers representing several distinct
biologic pathways associated with the ventricular re-
modeling process have recently been reported in a
large study27, supporting the same observation that
higher biomarker levels (hs-CRP and pro-BNP) are asso-
ciated with aging and increased RWT as in our current
study. Recently, decreased regional systolic function in LV
concentric remodeling was found in a magnetic reso-
nance imaging study28. Associated work regarding early
changes of LV systolic function when evaluated by tis-
sue Doppler imaging showed that increasing RWT was
related with lower LV strain and strain rate representing
subclinical ventricular dysfunction29.
In this study, a positive linear correlation between
RWT and age was observed. In line with previous lit-
erature reviews19–21,23, this relationship remained in-
dependent after multivariate adjustment for other
potential factors. The higher the systolic blood pressure,
the greater was the RWT. This relationship is compatible
with the traditional thought that the initial process
and pathogenesis of LV remodeling comes from ventricle
overload. Moreover, insulin level was also associated
with RWT in our study. The relationship between LV
remodeling and insulin resistance have been discussed
by other authors. Sundström et al.25 reported that LV
concentric remodeling is related to insulin resistance
syndrome in elderly men. In patients with hypertension,
insulin growth factor-1 as a trophic factor of ventricular
extracellular matrix turnover is an important and
independent determinant of RWT30. Moreover, uric
acid level also seemed to play an independent role in
the LV remodeling process from our current data, with
a higher uric acid level associated with higher RWT. In
animal models, interstitial purine metabolites were
increased in hearts with evidence of LV remodeling8,31.
Although the exact role of uric acid level in cardiovas-
cular disease has remained obscure so far, a close link
with metabolic abnormalities, including serum HbA1c,
glucose level and insulin resistance, have also been
reported recently in a clinical study32. In an Asian pop-
ulation, uric acid was found to be related to LV hyper-
trophy and remodeling in Japanese men33. In that
study, a higher uric acid level was predominantly asso-
ciated with ventricular hypertrophy in males alone,
but not actual remodeling. The real impact of serum
uric acid level on early LV structural alterations like
remodeling in the Asian population may need a future
survey with a larger sample size. Similar to previous
studies, the relationship between concentric geometry
and serum uric acid was confirmed in this study7,31. LV
hypertrophy was also related to chronic renal failure34.
In our study, however, the relationship between serum
creatinine and RWT was not significant.
To evaluate the impact of age on LV geometry, we
further analyzed the data in two different age groups
(≥ 60 years and < 60 years). The mean age difference
between the two groups was nearly 20 years, so they may
represent totally different age populations. Irrespective
of age, the mean blood pressure and glucose profiles
were mostly within normal ranges, and only a very small
number of participants had hypertension, diabetes or
received medications for hyperlipidemia. In both groups,
the majority of LV geometry was normal geometry with
a second-order prevalence to LV concentric remodeling.
In the current study, the proportion of concentric and
eccentric hypertrophy was relatively small when com-
pared with normal or concentric remodeling geometry.
Most of the cases with concentric geometry (RWT
> 0.42) were concentric remodeling without hypertro-
phy. The distribution of LV geography was different
from previous different cohorts2,35,36. The small per-
centage of hypertrophy in our study could be explained
by normal mean blood pressure with relatively healthy
baseline demographics, and may imply that the signif-
icant difference of all variables may come from the
effect of aging. Moreover, average RWT in the older
group was greater than that of the younger one. This
difference may translate into finding a higher prevalence
of concentric remodeling in the older group19–21,23.
Nevertheless, whether the existence of higher systolic
blood pressure in older people contributed to the in-
creased prevalence of concentric remodeling is un-
known, since the average blood pressure in both groups
was relatively low.
Limitations
Several limitations should be considered in this study.
First, this is a retrospective cross-sectional study, and
the sample size of the total and the elderly population
was relatively small compared with other studies. In
addition, the representative data of this study came
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from the participants of the health evaluation center,
and a wider clinical application and the relevance to 
a broader population may thus be limited. Although
our data may not completely hold true as being the
standard for a general Asian population, the smaller
percentage of comorbidities in our study, however,
may reflect a real-world situation rather than a specific
diseased population.
Furthermore, heart failure development with pre-
served ventricular ejection fraction resulting from LV
damage from coexisting hypertension, diabetes or other
metabolic abnormalities is becoming more and more
popular in clinical settings. However, the prevalence
of such diseases in our subjects was small and, thus,
beyond the scope of our study. Finally, other echocar-
diographic parameters that might help in detecting
and stratifying ventricular diastolic dysfunction, such as
the Doppler of mitral inflow or tissue Doppler imaging,
were not available in our database. A detailed coverage
of such parameters associated with aging or metabolic
abnormalities may be helpful, although such Doppler
evaluation might theoretically be more load-dependent
and less reproducible in clinical settings37.
Conclusion
Although the clinical significance of concentric remod-
eling was inconsistent from previous studies, we did
observe a close relationship between a minor phenotype
of geometric alterations with aging and other early
metabolic abnormalities. The normal aging process,
together with higher baseline systolic blood pressure or
some serum metabolic abnormalities, were all associ-
ated with LV geometric alterations in terms of concentric
remodeling. These data suggest that LV remodeling ac-
tually involves dynamic and complex interactions with
multiple clinical and metabolic factors in an unselected
general population living in Taiwan, and may possibly
impact future cardiovascular morbidities.
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